Antiva Biosciences, Inc.

Antiva Biosciences is a clinical-stage biopharmaceutical company in South San Francisco developing topical, self-administered antiviral therapeutics for diseases caused by human papillomavirus (HPV). Its lead candidate, ABI-2280, is a vaginal tablet designed to clear high-risk HPV infection and treat pre-cancerous cervical lesions (CIN 2,3) without surgery - an approach aimed at preserving reproductive health and supporting the WHO's goal of eliminating cervical cancer.